Empagliflozin findings the 'Holy Grail'

Adding empagliflozin to standard care for type 2 diabetes patients at high cardiovascular (CV) risk reduces mortality by up to 38%, a study shows.

The strong results come from a trial of more than 7000 patients from multiple centres, including Australia, the US and Europe.

Empagliflozin (Jardiance, Boehringer Ingelheim), the first of the SGLT2 inhibitors to